Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a growth hormone help people with End-Stage liver disease?

NCT ID NCT05253287

Disease control Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving growth hormone to people with decompensated liver cirrhosis (advanced liver scarring) could improve their health and survival. The trial included 96 adults with this condition. Researchers measured how long patients survived without major complications or needing a liver transplant, and checked for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

96 people

The number who actually took part.

Started

Feb 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age above 18 years. 2. Patients having confirmed diagnosis of decompensated cirrhosis, any etiology. 3. Patients having given an informed and written consent for participation in the study. Exclusion Criteria: 1. Acute on chronic liver failure. 2. Diagnosis of concomitant hepatocellular carcinoma or other active malignancy. 3. Severe cardiac dysfunction NYHA grade III/IV, Chronic obstructive pulmonary disease GOLD C or above. 4. Active alcohol abuse in last 3 months. 5. Known hypersensitivity to GH. 6. Human immunodeficiency virus seropositivity. 7. Patients on antiviral therapy for HCV, HBV or corticosteroid for autoimmune hepatitis those who have received it within the last 6 months. 8. TIPS insertion within 6 months prior to study inclusion. 9. Pregnancy \& lactation. 10. Uncontrolled diabetes (Hb A1c ≥ 9) or diabetic retinopathy. 11. Active sepsis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digestive system disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver Digestive System Diseases digestive system disorder End Stage Liver Disease Fibrosis fibrotic liver disease Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Digestive system disease End-stage liver disease Fibrosis Growth hormone treatment Liver cirrhosis Physiological effect of drugs Sarcopenia

Contacts and locations

Locations

  • Postgraduate Institute of Medical education and Research

    Chandigarh, Uttarakhand, 160012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.